论文部分内容阅读
目的:了解本院肝炎药物的基本用药状况和发展趋势,客观评估临床合理用药。方法:采用金额构成比、用药频度、日治疗费用及序号比分析的方法,对本院2008—2010年肝炎药物(不包括中成药和中药中的抗病毒药物)做统计分析。结果:2008—2010年肝炎药物的用药金额呈逐年增长趋势;消耗金额构成比前两位是注射用聚乙二醇干扰素(PEG-IFN)和注射用胸腺肽ɑ1;DDDs排前两位是口服药双环醇和拉米夫定。结论:本院肝炎药物应用随着药品的研发而有所变化,符合安全、有效、经济用药原则。
Objectives: To understand the basic medication status and development trend of hepatitis drugs in our hospital and to objectively evaluate the clinical rational drug use. Methods: Statistical analysis was conducted on hepatitis drugs (excluding proprietary Chinese medicines and Chinese antiviral drugs) from 2008 to 2010 in our hospital with the methods of amount composition ratio, frequency of medication, daily treatment cost and serial number ratio analysis. Results: The dosage of hepatitis drugs increased year by year from 2008 to 2010. The consumption amount of PEGylated interferon (PEG-IFN) and thymosin 1 for injection was higher than that of the first two. The top two DDDs were orally Medicinal bicyclol and lamivudine. Conclusion: The application of hepatitis drugs in our hospital has changed with the development of drugs, which is in line with the principle of safe, effective and economical medication.